Key result
ECCO2R lacks outcome benefits and carries significant bleeding risk despite achieving ultraprotective ventilation goals.
Why the study?
The clinical benefits and risk–benefit balance of ECCO2R in ARDS, obstructive lung failure, and bridging to lung transplantation remain unclear due to lack of evidence.
Does extracorporeal carbon dioxide removal (ECCO2R) improve outcomes in patients with ARDS or obstructive lung failure?
Does extracorporeal carbon dioxide removal (ECCO2R) improve outcomes in patients with ARDS or obstructive lung failure?
ECCO2R is not currently recommended as standard therapy for ARDS due to lack of outcome benefits and significant bleeding risks, and should be restricted to clinical studies and experienced centers.
No takes yet. Share an insight, caveat, or question.
Does not support routine ECCO2R use in ARDS; leaves its role in obstructive lung failure unresolved pending RCTs.
Thomas Staudinger (2024) conducted a review in Acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and lung transplantation bridging. Extracorporeal carbon dioxide removal (ECCO2R) was evaluated. Extracorporeal carbon dioxide removal (ECCO2R) achieves ultraprotective ventilation goals but has not demonstrated outcome benefits and carries a significant risk of bleeding complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: